Type 2 & other diabetes

Sodium–glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real‐world, cohort data

Diabetes Obes MetabPublished Retrospective cohort study

Main finding · Incident T2DResult — go to the resultHazard ratio 0.71 95% CI 0.63–0.75

Authors' conclusion

Treatment with SGLT2is in patients with HF was associated with a reduced risk of incident T2D, most strikingly in people with prediabetes.

Study context

Population
Patients with heart failure (HF) without baseline diabetes prescribed ACE inhibitors or angiotensin II receptor blockers, 95 global health care organizations39,168 each arm matched
Participants
484,643 patients
Exposure
ACEi/ARB with SGLT2i vs ACEi/ARB without SGLT2i
  • Treatmentn = 42,018
  • Referencen = 442,625reference
Outcome
Incident T2D
Methodological detailspropensity-score matched 1:1, 95 global health care organizations, real-world data
  • Propensity-score matched 1:1
  • 95 global health care organizations
  • Real-world data

Main finding

As reported in the abstract

Hazard ratio

0.71

95% CI 0.63–0.75

Treatmentvs Reference
HR 0.71 (95% CI 0.63–0.75)

Observational data: associations, not effects.

Secondary outcomes

Incident T2D, subgroup with prediabetes

HR (95% CI)
SGLT2is0.62 (0.45–0.80)

Incident T2D, dapagliflozin subgroup

HR (95% CI)
Dapagliflozin0.47 (0.39–0.56)

Incident T2D, empagliflozin subgroup

HR (95% CI)
Empagliflozin0.81 (0.70–0.93)
  • Incident T2D, empagliflozin subgroup: Reduction in incident T2D greater with dapagliflozin than empagliflozin

Original publication

Sodium–glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real‐world, cohort data. Diabetes Obes Metab. Published 7 August 2024. doi:10.1111/dom.15833

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.